This invention belongs to the technical field of
drug synthesis, specifically relating to
adamantane derivatives, their synthetic methods, and applications. The
adamantane derivatives described in this invention include intermediate structural formulas I, II, and III, as well as structures with the following general formula:
Linker is a substituted or unsubstituted C6-C10
aryl group; R1 is
hydrogen or a C1-C6
alkyl group; R2 is
hydrogen, a C1-C6
alkyl group, or a
nitrogen-containing or
nitrogen-free structural fragment; or the overall structure of R1R2 is an N-substituted heterocyclopentyl or heterocyclohexyl group. The
adamantane derivatives provided by this invention combine the adamantane structure with a portion of the OAB-14 group, altering the core structure and thus improving
drug activity. This invention also provides a synthetic method for these derivatives. Through
cellular activity studies, the resulting compounds are screened, demonstrating potential synergistic effects in the prevention of influenza and the treatment of Alzheimer's
disease.